Recommended Immunization Schedule for Persons Aged 0–6 Years—UNITED STATES • 2008

For those who fall behind or start late, see the catch-up schedule

**Vaccine ▼ Age ▶**

<table>
<thead>
<tr>
<th>Vaccine ▼</th>
<th>Age ▶</th>
<th>Birth</th>
<th>1 month</th>
<th>2 months</th>
<th>4 months</th>
<th>6 months</th>
<th>12 months</th>
<th>15 months</th>
<th>18 months</th>
<th>19–23 months</th>
<th>2–3 years</th>
<th>4–6 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B</td>
<td>HepB</td>
<td>HepB</td>
<td>see footnote 1</td>
<td>HepB</td>
<td>HepB</td>
<td>HepB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus</td>
<td>Rota</td>
<td>Rota</td>
<td>Rota</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria, Tetanus, Pertussis</td>
<td>DTaP</td>
<td>DTaP</td>
<td>DTaP</td>
<td>DTaP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae type b</td>
<td>Hib</td>
<td>Hib</td>
<td>Hib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal</td>
<td>PCV</td>
<td>PCV</td>
<td>PCV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated Poliovirus</td>
<td>IPV</td>
<td>IPV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, Mumps, Rubella</td>
<td>MMR</td>
<td>MMR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>HepA (2 doses)</td>
<td>HepA Series</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2007, for children aged 0 through 6 years. Additional information is available at www.cdc.gov/vaccines/recs/schedules. Any dose not administered at the recommended age should be administered at any subsequent visit, when indicated as feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used when any component of the combination is indicated and other components of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the respective Advisory Committee on Immunization Practices statement for detailed recommendations, including for high risk conditions: http://www.cdc.gov/vaccines/pubs/ACIP-list.htm. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete VAERS form is available at www.vaers.hhs.gov or by telephone, 800-822-7967.

1. Hepatitis B vaccine (HepB). (Minimum age: birth)
   - At birth:
     - Administer monovalent HepB to all newborns prior to hospital discharge.
     - If mother is hepatitis B surface antigen (HBsAg)-positive, administer HepB and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth.
     - If mother’s HBsAg status is unknown, administer HepB within 12 hours of birth. Determine the HBsAg status as soon as possible and if HepB-positive, administer HBIG (no later than 1 week).
   - If mother is HBsAg-negative, the birth dose can be delayed, in rare cases, with a provider’s order and a copy of the mother’s negative HBsAg laboratory report in the infant’s medical record.

   After the birth dose:
   - The HepB series should be completed with either monovalent HepB or a combination vaccine containing HepB. The second dose should be administered at age 1–2 months. The final dose should be administered no earlier than age 24 weeks. Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg after completion of at least 3 doses of a licensed HepB series, at age 9–18 months (generally at the next well-child visit).

   4-month dose:
   - It is permissible to administer 4 doses of HepB when combination vaccines are administered after the birth dose. If monovalent HepB is used for doses after the birth dose, a dose at age 4 months is not needed.

2. Rotavirus vaccine (Rota). (Minimum age: 6 weeks)
   - Administer the first dose at age 6–12 weeks.
   - Do not start the series later than age 12 weeks.
   - Administer the final dose in the series by age 32 weeks. Do not administer any dose later than age 32 weeks.
   - Data on safety and efficacy outside of these age ranges are insufficient.

3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). (Minimum age: 6 weeks)
   - The fourth dose of DTaP may be administered as early as age 12 months, provided 6 months have elapsed since the third dose.
   - Administer the final dose in the series at age 4–6 years.

4. Haemophilus influenzae type b conjugate vaccine (Hib). (Minimum age: 6 weeks)
   - If PRP-OMP (PedvaxHIB® or ComVax™ [Merck]) is administered at ages 2 and 4 months, a dose at age 6 months is not required.
   - TriHIBit® (DTaP/Hib) combination products should not be used for primary immunization but can be used as boosters following any Hib vaccine in children age 12 months or older.

5. Pneumococcal vaccine. (Minimum age: 6 weeks for pneumococcal conjugate vaccine [PCV]; 2 years for pneumococcal polysaccharide vaccine [PPV])
   - Administer one dose of PCV to all healthy children aged 24–59 months having any incomplete schedule.
   - Administer PPV to children aged 2 years and older with underlying medical conditions.

6. Influenza vaccine. (Minimum age: 6 months for trivalent inactivated influenza vaccine [TIV]; 2 years for live, attenuated influenza vaccine [LAIV])
   - Administer annually to children aged 6–59 months and to all close contacts of children aged 0–59 months.
   - Administer annually to children 5 years of age and older with certain risk factors, to other persons (including household members) in close contact with persons in high risk groups, and to any child whose parents request vaccination.
   - For healthy nonpregnant persons (those who do not have underlying medical conditions that predispose them to influenza complications) ages 2–49 years, either LAIV or TIV may be used.
   - Children receiving TIV should receive 0.25 mL if age 6–35 mos or 0.5 mL if age 3 years or older.
   - Administer 2 doses (separated by 4 weeks or longer) to children younger than 9 years who are receiving influenza vaccine for the first time or who were vaccinated for the first time last season, but only received one dose.

7. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)
   - Administer the second dose of MMR at age 4–6 years. MMR may be administered before age 4–6 years, provided 4 weeks or more have elapsed since the first dose.

8. Varicella vaccine. (Minimum age: 12 months)
   - Administer second dose at age 4–6 years; may be administered 3 months or more after first dose.
   - Don’t repeat second dose if administered 28 days or more after first dose.

9. Hepatitis A vaccine (HepA). (Minimum age: 12 months)
   - HepA is recommended for all children aged 1 yr (i.e., aged 12–23 months).
   - The 2 doses in the series should be administered at least 6 months apart. Children not fully vaccinated by age 2 years can be vaccinated at subsequent visits.
   - HepA is recommended for certain other groups of children, including in areas where vaccination programs target older children.

10. Meningococcal vaccine. (Minimum age: 2 years for meningococcal conjugate vaccine [MCV4] and for meningococcal polysaccharide vaccine [MPSV4])
    - MCV4 is recommended for children aged 2–10 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. Use of MPSV4 is also acceptable.
    - Persons who received MPSV4 3 or more years prior and remain at increased risk for meningococcal disease should be vaccinated with MCV4.
### Recommended Immunization Schedule for Persons Aged 7–18 Years

For those who fall behind or start late, see the green bars and the catch-up schedule

<table>
<thead>
<tr>
<th>Vaccine ▼</th>
<th>Age ▼</th>
<th>7-10 years</th>
<th>11-12 years</th>
<th>13-18 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphtheria, Tetanus, Pertussis³</td>
<td>see footnote 1</td>
<td>Tdap</td>
<td>Tdap</td>
<td></td>
</tr>
<tr>
<td>Human Papillomavirus²</td>
<td>see footnote 2</td>
<td>HPV (3 doses)</td>
<td>HPV Series</td>
<td></td>
</tr>
<tr>
<td>Meningococcal³</td>
<td></td>
<td>MCV4</td>
<td>MCV4</td>
<td>MCV4</td>
</tr>
<tr>
<td>Pneumococcal⁴</td>
<td></td>
<td>PPV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza⁵</td>
<td></td>
<td>Influenza (Yearly)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A⁶</td>
<td></td>
<td>HepA Series</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B⁷</td>
<td></td>
<td>HepB Series</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated Poliovirus⁸</td>
<td></td>
<td>IPV Series</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, Mumps, Rubella⁹</td>
<td></td>
<td>MMR Series</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella¹⁰</td>
<td></td>
<td>Varicella Series</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2007, for children aged 7–18 years. Additional information is available at www.cdc.gov/vaccines/recs/schedules. Any dose not administered at the recommended age should be administered at any subsequent visit, when indicated and feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and other components of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the respective Advisory Committee on Immunization Practices statement for detailed recommendations, including for high risk conditions: http://www.cdc.gov/vaccines/pubs/ACIP-list.htm. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete VAERS form is available at www.vaers.hhs.gov or by telephone, 800-822-7967.

---

1. **Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap).** *(Minimum age: 10 years for BOOSTRIX® and 11 years for ADACEL™)*
   - Administer at age 11–12 years for those who have completed the recommended childhood DTP/DTaP vaccination series and have not received a tetanus and diphtheria toxoids (Td) booster dose.
   - 13–18 year olds who missed the 11–12 year Tdap or received Td only, are encouraged to receive one dose of Tdap 5 years after the last Td/DTaP dose.

2. **Human papillomavirus vaccine (HPV).** *(Minimum age: 9 years)*
   - Administer the first dose of the HPV vaccine series to females at age 11–12 years.
   - Administer the second dose 2 months after the first dose and the third dose 6 months after the first dose.
   - Administer the HPV vaccine series to females at age 13–18 years if not previously vaccinated.

3. **Meningococcal vaccine.**
   - Administer MCV4 at age 11–12 years and at age 13–18 years if not previously vaccinated. MPSV4 is an acceptable alternative.
   - Administer MCV4 to previously unvaccinated college freshmen living in dormitories.
   - MCV4 is recommended for children aged 2-10 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups.
   - Persons who received MPSV4 3 or more years prior and remain at increased risk for meningococcal disease should be vaccinated with MCV4.

4. **Pneumococcal polysaccharide vaccine (PPV).**
   - Administer PPV to certain high-risk groups.

5. **Influenza vaccine.**
   - Administer annually to all close contacts of children aged 0–59 months.
   - Administer annually to persons with certain risk factors, health-care workers, and other persons (including household members) in close contact with persons in groups at higher risk.

6. **Hepatitis A vaccine (HepA).**
   - The 2 doses in the series should be administered at least 6 months apart.
   - HepA is recommended for certain other groups of children, including in areas where vaccination programs target older children.

7. **Hepatitis B vaccine (HepB).**
   - Administer the 3-dose series to those who were not previously vaccinated.
   - A 2-dose series of Recombivax HB® is licensed for children aged 11–15 years.

8. **Inactivated poliovirus vaccine (IPV).**
   - For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if the third dose was administered at age 4 years or older.
   - If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child’s current age.

9. **Measles, mumps, and rubella vaccine (MMR).**
   - If not previously vaccinated, administer 2 doses of MMR during any visit, with 4 or more weeks between the doses.

10. **Varicella vaccine.**
    - Administer 2 doses (separated by 4 weeks or longer) to children younger than 9 years who are receiving influenza vaccine for the first time or who were vaccinated for the first time last season, but only received one dose.
    - For healthy nonpregnant persons (those who do not have underlying medical conditions that predispose them to influenza complications) ages 2–49 years, either LAIV or TIV may be used.

---

The Recommended Immunization Schedules for Persons Aged 0–18 Years are approved by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/recs/acip), the American Academy of Pediatrics (http://www.aap.org), and the American Academy of Family Physicians (http://www.aafp.org).

DEPARTMENT OF HEALTH AND HUMAN SERVICES • CENTERS FOR DISEASE CONTROL AND PREVENTION
SAFER • HEALTHIER • PEOPLE™
### Catch-up Immunization Schedule for Persons Aged 4 Months–18 Years Who Start Late or Who Are More Than 1 Month Behind

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child’s age.

#### CATCH-UP SCHEDULE FOR PERSONS AGED 4 MONTHS–6 YEARS

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Minimum Age for Dose 1</th>
<th>Minimum Interval Between Doses</th>
<th>Dose 1 to Dose 2</th>
<th>Dose 2 to Dose 3</th>
<th>Dose 3 to Dose 4</th>
<th>Dose 4 to Dose 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Birth</td>
<td>8 weeks (as final dose)</td>
<td>8 weeks</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus&lt;sup&gt;2&lt;/sup&gt;</td>
<td>4 weeks</td>
<td>HEPB is not recommended for children 13–18 years</td>
<td>8 weeks</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria,Tetanus,Pertussis&lt;sup&gt;3&lt;/sup&gt;</td>
<td>6 wks</td>
<td>if current age is 12–15 months</td>
<td>4 weeks</td>
<td>4 weeks</td>
<td>8 weeks (as final dose)</td>
<td>8 weeks (as final dose)</td>
</tr>
<tr>
<td>Haemophilus influenza type b&lt;sup&gt;4&lt;/sup&gt;</td>
<td>6 wks</td>
<td>if current age is 12–15 months</td>
<td>8 weeks (as final dose)</td>
<td>4 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal&lt;sup&gt;5&lt;/sup&gt;</td>
<td>6 wks</td>
<td>if current age is 12–15 months</td>
<td>8 weeks (as final dose)</td>
<td>4 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated Poliovirus&lt;sup&gt;6&lt;/sup&gt;</td>
<td>6 wks</td>
<td>if current age is 12–15 months</td>
<td>8 weeks (as final dose)</td>
<td>4 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, Mumps, Rubella&lt;sup&gt;7&lt;/sup&gt;</td>
<td>12 mos</td>
<td>if current age is 12–15 months</td>
<td>8 weeks (as final dose)</td>
<td>4 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella&lt;sup&gt;8&lt;/sup&gt;</td>
<td>12 mos</td>
<td>if current age is 12–15 months</td>
<td>8 weeks (as final dose)</td>
<td>4 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A&lt;sup&gt;9&lt;/sup&gt;</td>
<td>12 mos</td>
<td>if current age is 12–15 months</td>
<td>8 weeks (as final dose)</td>
<td>4 weeks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### CATCH-UP SCHEDULE FOR PERSONS AGED 7–18 YEARS

1. **Hepatitis B vaccine (HepB).**
   - Administer the 3-dose series to those who were not previously vaccinated.
   - A 2-dose series of Recombivax HB® is licensed for children aged 11–15 years.

2. **Rotavirus vaccine (Rotavirus).**
   - Do not start the series later than age 12 weeks.
   - Administer the final dose in the series by age 32 weeks.
   - Do not administer a dose later than age 26 weeks.
   - Data on safety and efficacy outside of these age ranges are insufficient.

3. **Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP).**
   - The fifth dose is not necessary if the fourth dose was administered at age 4 years or older.
   - DTaP is not indicated for persons aged 7 years or older.

4. **Haemophilus influenzae type b conjugate vaccine (Hib).**
   - Vaccine is not generally recommended for children aged 5 years or older.
   - If current age is younger than 12 months and the first 2 doses were PRP-OMP (PedvaxHIB® or Comvax® [Merck]), the third (and final) dose should be administered at age 12–15 months and at least 8 weeks after the second dose.
   - If first dose was administered at age 7–11 months, administer 2 doses separated by 4 weeks plus a booster at age 12–15 months.

5. **Pneumococcal conjugate vaccine (PCV).**
   - Administer one dose of PCV to all healthy children aged 24–59 months having no incomplete schedule.
   - For children with underlying medical conditions administer 2 doses of PCV at least 8 weeks apart if previously received less than 3 doses or 1 dose of PCV if previously received 3 doses.

6. **Inactivated poliovirus vaccine (IPV).**
   - For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if third dose was administered at age 4 years or older.
   - • If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child’s current age.
   - • IPV is not routinely recommended for persons aged 18 years or older.

7. **Measles, mumps, and rubella vaccine (MMR).**
   - The second dose of MMR is recommended routinely at age 4–6 years but may be administered earlier if desired.
   - • If not previously vaccinated, administer 2 doses of MMR during any visit with or 4 more weeks between the doses.

8. **Varicella vaccine.**
   - The second dose of varicella vaccine is recommended routinely at age 4–6 years but may be administered earlier if desired.
   - • Do not repeat the second dose in persons younger than 13 years of age if administered 28 or more days after the first dose.

9. **Hepatitis A vaccine (HepA).**
   - HepA is recommended for certain groups of children, including in areas where vaccination programs target older children. See MMWR 2006;55(RR-7):1–23.

10. **Tetanus and diphtheria toxoids vaccine (Td) and tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap).**
    - • Tdap should be substituted for a single dose of Td in the primary catch-up series or as a booster as appropriate; use Td for other doses.
    - • A 5-year interval from the last Td dose is encouraged when Tdap is used as a booster dose. A booster (fourth) dose is needed if any of the previous doses were administered at younger than 12 months of age. Refer to ACP recommendations for further information. See MMWR 2006;55(RR-3).

11. **Human papillomavirus vaccine (HPV).**
    - Administer the HPV vaccine series to females at age 13–18 years if not previously vaccinated.

---

Information about reporting reactions after immunization is available online at [http://vaers.hhs.gov](http://vaers.hhs.gov) or by telephone via the 24-hour national toll-free information line 800-822-7967.

Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. Additional information, including precautions and contraindications for immunization, is available from the National Center for Immunization and Respiratory Diseases at [http://www.cdc.gov/vaccines](http://www.cdc.gov/vaccines) or telephone 800-CDC-INF0 (800-232-4636).